Clinical trial
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX®…
NCT00432523 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00432523 |
|---|---|
| Title | Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) |
| Official title | An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of M-M-R™II Manufactured With Recombinant Human Albumin (rHA) and VARIVAX® When Administered Concomitantly by Intramuscular (IM) Route or Subcutaneous (SC) Route at Two Separate Injection Sites in Healthy Subjects… |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Measles, Mumps, Varicella |
| Intervention type | Biological |
| Interventions | M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® |
| Enrollment | 752 |
| Start date | Jan 20, 2005 |
| Primary completion | Sep 5, 2005 |
| Completion | Sep 5, 2005 |
| First posted | Feb 8, 2007 |
| Last update posted | Oct 18, 2021 |
| Countries | France, Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: